Michael Maguire, Ph.D., CEO
Kildare, Ireland
Avectas is a cell engineering technology business focused on improving the cost, manufacturing, and patient outcomes for the next generation of cellular therapies. Avectas is developing a unique cell engineering platform, SOLUPORE™, to enable the ex vivo manufacture of gene modified cell therapy products. SOLUPORE™ is a patented, non-viral, cell engineering technology that permeabilizes the target cell membrane and allows efficient transfer of cargo into cells whilst retaining very high levels of cell viability and functionality.

By using this website you agree to accept our Privacy Policy and Terms & Conditions